Subscribe to Newsletter
Discovery & Development COVID-19, Drug Discovery, Standards & Regulation, Vaccines

Selfishness and Stupidity?

The end of February saw the FDA approve another COVID-19 vaccine: Janssen’s single-shot vaccine – developed using the company’s AdVac platform (1). Janssen has also applied for conditional marketing authorization with the EMA.

What the scientific community has achieved in terms of COVID-19 vaccine development over the last 12 months is incredible, but it’s not over yet. A number of SARS-CoV-2 variants could affect the efficacy of current vaccines; for instance, the Oxford/AstraZeneca vaccine was reported to be less effective at preventing COVID-19 cases caused by the “South African” variant of the virus – and roll out has been halted in South Africa (2).

But action is being taken. Pfizer and BioNTech recently commenced a study looking at a third dose of its vaccine and how it protects against newly emerging SARS-CoV-2 variants (3). The FDA has released policies to guide developers addressing variants and the EMA has issued guidance that outlines requirements for vaccine manufacturers that are planning to modify their vaccines (4,5).

I’m not worried about the science or vaccine success. The pharma industry has already proven it is up to the task. 

I am concerned about the public. Though many people applaud the speed at which pharma has moved, others are suspicious that the vaccines are rushed and unsafe. COVID-19 vaccine conspiracy stories are rife. For a person of average intelligence, conspiracy theories are often mildly entertaining works of fiction, but the anti-vaccination movement is downright dangerous. Outbreaks of measles in recent years in the US have been linked to anti-vaxxers. And during the COVID-19 pandemic, doctors and healthcare workers advocating for vaccination have even received death threats (6).

A UK survey conducted at the end of 2020 found that most British people consider anti-vaxxers “selfish” and “stupid” (7). But experts have also warned that negative attitudes towards anti-vaxxers are part of the problem and will do little to persuade doubters to change their views. A UK university is currently setting up a global taskforce to examine the issues of vaccine hesitancy – and has received £2.7 million (around US$3.7 million) under the EU’s Horizon 2020 program (8). The taskforce will “systematically” investigate vaccination attitudes among healthcare workers and analyze the arguments made by anti-vaccination activists to develop tools and techniques to challenge and refute such claims.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. FDA, “FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine,” (2021). Available at
  2. E Mahase, “Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant,” BMJ, 372 (2021). DOI: 10.1136/bmj.n372 
  3. Pfizer, “Pfizer And Biontech Initiate A Study As Part Of Broad Development Plan To Evaluate Covid-19 Booster And New Vaccine Variants,” (2021). Available at
  4. FDA, “FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants,” (2021). Available at
  5. EMA, “Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers,” (2021). Available at
  6. Time, “The Vaccine Champions in France Defying Death Threats to Convert Anti-Vaxxers,” (2021). Available at
  7. King’s College London, “How the public and social media users view anti-vaxxers,” (2020). Available at
  8. University of Bristol, “Global taskforce set to demystify and overcome vaccine hesitancy amid COVID-19 pandemic,” (2021). Available at
About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine